Mirati Therapeutics, Inc. (MRTX): Ltd. Braslyn , 10% owner of Mirati Therapeutics, Inc. purchased 65,782 shares on May 5, 2016. The Insider buying transaction was reported by the company on May 9, 2016 to the Securities and Exchange Commission. The shares were purchased at $17.72 per share for a total value of $1,197,905.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 28, 2016, Ltd. Braslyn (10% owner) purchased 20,848 shares at $19.42 per share price.On Jan 19, 2016, Mark J Gergen (Executive VP, COO) sold 10,000 shares at $25.92 per share price.Also, On May 27, 2015, Jamie Christensen (SVP & Chief Scientific Officer) sold 4,750 shares at $28.07 per share price.
Shares of Mirati Therapeutics (MRTX) ended Friday, May 6, 2016 session in red amid volatile trading. The shares closed down -3 points or -15.87% at $15.9 with 5,03,753 shares getting traded. Post opening the session at $18.01, the shares hit an intraday low of $14.5901 and an intraday high of $18.1699 and the price vacillated in this range throughout the day. The company has a market cap of $307 M and the number of outstanding shares has been calculated to be 1,93,02,313 shares. The 52-week high of Mirati Therapeutics is $52 and the 52-week low is $14.5901.
Company has been under the radar of several Street Analysts.Mirati Therapeutics is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 41 from a previous price target of $45 . The Rating was issued on May 9, 2016.Mirati Therapeutics is Initiated by Sun Trust Rbsn Humphrey to Buy and the brokerage firm has set the Price Target at $32. The Rating was issued on Mar 2, 2016.Mirati Therapeutics is Resumed by Jefferies to Buy. The Rating was issued on Feb 17, 2016.